A week of endpoint misses and trial halts: BioCentury’s Clinical Report

Missed endpoints, adverse events and discontinued trials dominated the set of clinical results reported over the last seven days.

BioCentury’s clinical results scorecard for the period shows only two companies saw stock gains after clinical announcements, and one of them appeared unrelated to the clinical news...